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introduction: Dystrophin deficiency associated with Duchene muscular 
dystrophy (DMD) results in chronic inflammation and severe skeletal muscle 
degeneration, where the extent of muscle fibrosis contributes to disease severity. 
The microenvironment of dystrophic muscles is associated with variation in 
levels of cytokine and growth factors. Most of the current researches test for 
such cytokines and growth factors in tissue biopsies, which is an invasive 
technique.
the aim: Of the present study is to investigate whether cytokines and growth 
factors, as indicators of inflammatory response, can be detected in blood of 
DMD patients as non-invasive technique. 
Patient and Methods: Accordingly the cytokine tumor necrosis factor alfa 
(TNF TNF-α), as well as the growth factors basic fibroblast growth factor 
(bFGF) and vascular endothelial growth factor (VEGF) were measured in 
blood of 24 boys with DMD diagnosed clinically and at the molecular level 
versus 20 age matching healthy boys. 
results: Showed a significant increases in TNF-ά (30.2 ± 9.5 vs. 3.6 ± 0.9 pg/
ml) and bFGF (21.7 ± 10.3 vs. 4.75 ± 2.2 pg/ml.), while VEGF was significantly 
decreased (190 ± 115 vs. 210 ± 142 pg/ml) in blood of DMD patients compared 
to controls. 
conclusion: Results provide further proof that inflammatory response is 
associated with DMD pathogenesis and favours the use of biomarkers in blood 
of such patients as a non invasive technique.
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introDUction                                           
DMD is an X-linked recessive disorder, 
primarily characterizebd by progressive 
muscle weakness and waisting. Muta-
tions in dystrophin gene are the prime 
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cause for muscle degeneration asso-
ciated with DMD1. Normally dystro-
phin interacts with several members of 
the dystrophin glycoprotein complex, 
which forms a mechanical as well as 
signaling link from the extracellular 
matrix to the cytoskeleton2. Mutations 
in dystrophin result in membrane dam-
age, allowing massive infiltration of 
immune cells, chronic inflammation, 
necrosis, and severe muscle degenera-
tion3. Normally, muscle cells possess 
the capacity to regenerate in response 
to injury signals4, however, this abil-
ity is lost in DMD, presumably due to 
an exhaustion of satellite cells during 
ongoing degeneration and regeneration 
cycles5. Although dystrophin mutations 
represent the primary cause of DMD, 
it is the secondary processes involving 
persistent inflammation and impaired 
regeneration that likely exacerbate dis-
ease progression. This results in chronic 
inflammation and severe skeletal mus-
cle degeneration, where the extent of 
muscle fibrosis contributes to disease 
severity. Elevated numbers of inflam-
matory cells are known to be present at 
the sites of muscle injuries and interact 
together for cytokine and growth fac-
tors signaling.6-9 
TNF-α is an early and potent pro-in-
flammatory cytokine that stimulates 
the inflammatory response. Even minor 
trauma to muscle will increase levels 
of TNF-α by release from mast cells; 
TNF-α is also produced by neutrophils, 
macrophages and lymphocytes that ac-
cumulate rapidly at the site of injury. 
TNF-α increases rapidly within dam-
aged myofibers and is expressed by 
myoblasts and myotubes10-12. TNF-α is 
greatly elevated in injured normal dam-
aged myofibers10,11 and myopathic skel-
etal muscle13, it is chemotactic for myo-
blasts14 and is mitogenic for satellite 
cells in vivo, suggesting a direct role in 
myogenesis of regenerating muscle.10
Muscle tissue repair is a complex bio-
logical process that crucially involves 
activation of stem cells. Skeletal muscle 
contains two different stem cell types: 1 
myogenic stem cells, so-called satellite 
cells (SCs), that reside beneath the bas-
al lamina of muscle fibers15,2 interstitial 
multipotent stem cells, which are extra-
laminal, exhibit fibroblastic morphol-
ogy and do not express myogenic mark-
ers16. SCs represent the pre-eminent 
muscle stem cell type used for muscle 
growth, repair and regeneration17. They 
are primarily quiescent in skeletal mus-
cle, can self-renew and upon activation, 
proliferate and further differentiate to 
become fusion-competent myoblasts 
and ensure muscle regeneration18. Inter-
stitial “muscle-derived” stem cells give 
rise to several lineages after transplan-
tation and in this setting, contribute to 
synchronized reconstitution of blood 
vessels (pericytes, smooth muscle cells 
[SMCs], and endothelial cells), periph-
eral nerve (Schwann cells), and muscle 
cells (myofibers and SCs;16. However, 
participation of multipotent interstitial 
stem cells in physiological muscle re-
pair appears to be limited. 
Satellite cells could excrete growth fac-
tors including VEGF that would induce 
angiogenesis and improve cell surviv-
al.19. The VEGF is the prototypic mem-
ber of a family of secreted, homodimeric 
glycoproteins with endothelial cell-spe-
cific mitogenic activity and the ability 
to stimulate angiogenesis in vivo20. On 
the other hand, a number of growth fac-
tors such as fibroblast growth factor 
(FGF) can promote the activation and 
proliferation of skeletal satellite cells.21 
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Basic FGF contributes to promote pro-
liferation and to inhibit differentiation 
of skeletal muscles.22
The aim of the present study is to inves-
tigate levels of cytokines (TNF-α) and 
growth factors (VEGF and bFGF) in-
volved in muscle regeneration in blood 
of DMD patients compared to controls.
Patient anD MetHoDS            
Subjects were23 DMD boys diagnosed 
clinically and at the molecular level 
(mean age (8.1 ± 1.9) years versus 
20 age and socioeconomic matching 
healthy boys (mean of age 8.2 ± 2.2). 
Patients and controls were chosen to 
be free from any infection and receiv-
ing no therapeutic treatment known 
to increase the oxidative stress. Blood 
samples were drawn after their parents’ 
consent.
Plasma analysis was performed for cy-
tokine (TNF-ά) using elisa/PCR (24), 
growth factor VEGF using the AC-
CUCYTE Human VEGF immunoassay 
kit 24 and  bFGF using human bFGF im-
munosorbant assay (ELIZA) Quantitin 
kit.25 
Statistical analysis: 
Each experimental condition was per-
formed and expressed as mean ± SD. 
Comparisons were made by Student’s 
t-test (two-tailed for independent sam-
ples).
reSUltS                                             
TNF and bFGF were significantly high-
er in Blood of DMD patients compared 
to controls (Table 1, Figures 1 & 2)TNF 
was (30.2 ± 9.5 vs. 3.6 ± 0.9 pg/ml) and 
bFGF was (21.7 ± 10.3 vs. 4.75  ±  2.2). 
In contrast, VEGF significantly lower 
in blood of DMD patients compared to 
controls. (190 ± 115 vs. 210 ± 142). 
table 1: TNF, bFGF and VEGF in blood of 
DMD patients compared to controls.
tnF          
pg/ml






30.2 ±  9.5 21.7± 10.3 190 ± 115
Controls 3.6 ± 0.9 4.75 ± 2.2 210 ± 142
t 14 17 4.2
p p <0.00001 < 0.00005 < 0.005
Fig. 1: TNF, and bFGF in Blood of DMD pa-
tients compared to controls. 
Fig. 2: VEGF in Blood of DMD Patients 
Compared to Controls.
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DiScUSSion                                        
In normal skeletal muscles, damage 
due to contractile force is followed by 
an inflammatory response involving 
multiple cell types that subsides after 
several days. This transient inflamma-
tory response is a normal homeostatic 
reaction to muscle damage that induces 
muscle repair. However in DMD pa-
tients a persistent inflammatory re-
sponse in their skeletal muscles leads 
to an altered extracellular environment, 
including an increased presence of in-
flammatory cells (e.g., macrophages) 
and elevated levels of various inflam-
matory cytokines and growth factors. 
Unfortunately, the signals that lead to 
successful muscle repair in healthy 
muscle may promote muscle waisting 
and fibrosis in dystrophic muscles26. 
Our results point to increase in inflam-
matory cytokines TNF-ά and growth 
factor bFGF in blood of DMD patients, 
while VEGF exhibited a significant de-
crease compared to controls.
TNF-α is an important mediator of in-
flammatory and autoimmune diseases. It 
was reported that the mean serum TNF-
αconcentration in Duchenne muscular 
dystrophy patients was approximately 
1,000 times higher than that in healthy 
subjects10 and that TNF-α levels are up-
regulated in dystrophic muscles from 
animal models and DMD patients4,6. 
Among its pleiotropic effects, TNF-α 
acts as a potent inducer of the inflamma-
tory response transcription factor NF-
κB27,28. Although dystrophin mutations 
represent the primary cause of DMD, 
it is the secondary processes involving 
persistent inflammation and impaired 
regeneration that likely exacerbate dis-
ease progression. The microenviron-
ment of dystrophic muscles consists of 
elevated numbers of inflammatory cells 
that act as a complex interface for cy-
tokine signaling4, 6. It is emphasized that 
TNF contribute to myofibre necrosis, 
where antibody depletion of host neu-
trophils resulted in a delayed and sig-
nificantly reduced amount of skeletal 
muscle breakdown in young dystrophic 
mdx mice.29 
Results of the present study showed 
increased levels of bFGF compared to 
controls. Growth factors, represent es-
sential elements in the modulation of 
muscle cell regeneration and differen-
tiation4.Interestingly, many growth fac-
tors, including basic fibroblast growth 
factor (bFGF), has been shown to be up-
regulated in mdx mice30 and serum lev-
els has been shown to increase in DMD 
patients compared to controls31. How-
ever, bFGF role in DMD pathogenesis 
is still unclear. Moreover, disruption 
of muscle membrane repair machinery 
results in progressive muscular dystro-
phy in the presence of a functional dys-
trophn glycogen32. It is suggested that 
DMD lack dystrophin and as a result 
their skeletal muscles show extensive 
muscle fiber damage and fibrosis, and 
regeneration33. This is also supported by 
data obtained from experiments carried 
out on mdx mice, which are larger than 
normal mice. Mdx have been noted to 
show larger limb muscles than normal 
mice; however, the larger muscles of 
mdx mice are actually weaker than those 
of normal mice due to extensive fibrosis 
and the lower potential for force gen-
eration by newly regenerated fibers34,35. 
Mdx mice have a large number of de-
generating and regenerative muscle fi-
bers in the first 4 months of life, after 
which the number of degenerative and 
necrotic fibers declines.35 
In the present study VEGF was signifi-
cantly lower in DMD patients compared 
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to controls. Exercise is known to increase 
muscle VEGF mRNA36-38  and DMD pa-
tients usually have limited physical ac-
tivity, which can explain the lower level 
of VEGF in our DMD patients. Data 
obtained from comparative studies on 
young and ageing muscle and on exer-
cised and sedentary muscles, indicated 
that in aged compared with young men, 
muscle capillary contacts and capillary-
to-fiber perimeter exchange index were 
lower and that VEGF muscle protein 
decreases with ageing39,40. Replica-
tive aging of myogenic cells (satellite 
cells), owing to enhanced myofiber 
turnover, is an accepted common ex-
planation of the progression of DMD 
pathogenesis41. Studies supporting our 
finding can be obtained from a previous 
study that showed that intramuscular 
delivery of VEGF using recombinant 
adeno-associated virus (rAAV) vec-
tors in mdx mice induced an increased 
forelimb strength and strength nor-
malized to weight42. Another example 
supporting replicative ageing theory is 
that mdx mice transplant injected with 
muscle precursor cells into tibialis ex-
hibited Graft success. This was evalu-
ated as the percentage of improvement 
of hybrid fibers by 1.9-fold after swim-
ming 3 times per week during 4 weeks. 
It was suggested that exercise induced 
fiber breaks, which improved muscle 
precursor cells recruitment and fusion 
and increased long-term graft success 
and also transverse and longitudinal 
distribution of hybrid fibers.43 
conclUSion                                     
Growth factors and cytokines are asso-
ciated with DMD pathogenesis, where 
TNF, bFGF and VEGF can give a re-
flection of the severity of DMD pathol-
ogy. Detecting such growth factors and 
cytokines biomarkers in blood of DMD 
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